Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was originally approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes (T2D). Current ...

At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Ozempic (semaglutide) is a subcutaneous injection used in people with type 2 diabetes. It may cause mild side effects, such as abdominal pain, or more serious side effects, such as diabetic ...

Hims & Hers’ Super Bowl ad plugs its compounded weight loss drugs as the “affordable” solution to a “sick system,” but many concerns about safety still swirl around these forms of the ...

In one study, seven patients (26%) presenting with foot drop had had recent IM injections in the buttock. An additional 20 patients (74%) presented much later (Fatunde & Familusi, 2001).

"I was looking for a small central apartment with character, and when I saw this space I thought it was perfect for my needs, ...